ClinPGx Blog (Page 50)

Sign in Subscribe

More issues

Curators Favorite Papers

The current Curators Favorite Papers are about the pharmacogenetics of statins. The review by Postmus et al. discusses achievements, whole-genome analyses and future perspectives [PMID: 22594514]. Van der Baan et al. investigate the value of pharmacogenetic testing in predicting statin response using data from the REGRESS trail [PMID: 22547143]

CPIC publishes guideline for SLCO1B1 and simvastatin-induced myopathy

Statins are among the most commonly prescribed drugs in the world to treat hypercholesterolemia and prevent cardiovascular diseases. They effectively lower cholesterol levels by inhibiting the HMG-CoA reductase, the rate limiting enzyme involved in cholesterol formation. Though well tolerated in general, statins can lead to myopathy with symptoms ranging

Vitamin D receptor (VDR) polymorphisms and treatment responses

The human VDR protein is trans-acting transcriptional factor. It binds the active form of vitamin D (1,25-dihydroxyvitamin D3) to modulate many biological activities of the neural, immune and endocrine systems. Poon et al. have recently written an updated Very Important Pharmacogene (VIP) Summary for VDR gene that

SFSU Personalized Medicine Conference - the role of epigenetics

See you at the San Francisco State University Personalized Medicine Conference 5.0, which this year focuses on epigenetics with speakers from academia and industry. Thursday 24th May, 8:00am-7:30pm South San Francisco Conference Center

Bay Area Biotechnology Symposium - Pharmaceuticals for the Future

UCSF School of Pharmacy, Industry Outreach Program is hosting a Bay Area Biotechnology Symposium tomorrow discussing the problems and solutions of developing Pharmaceuticals for the Future. It is open to all audiences...see you there! Saturday 19th May 2012 9:00am to 1:00pm Genentech Hall, Byers Auditorium, UCSF Mission

Curators Favorite Papers

The current Curators Favorite Papers are selected around pharmacogenetics of smoking cessation and nicotine metabolism. The review by Gold & Lerman [PMID: 22290489] discusses evidence for the association of cholinergic and nicotine metabolism gene variations with smoking cessation and therapeutic response. The article by Binnington et al. [PMID: 22569203] studied

NAT1 Haplotype table now available on PharmGKB

Haplotype tables are useful recent additions to PharmGKB, and the latest addition to the set is for NAT1 (N-acetyltransferase 1). The main source for this table was the University of Louisville School of Medicine Arylamine N-acetyltransferase Gene Nomenclature Committee website. The PharmGKB haplotype tables, located on tabs of

Understanding the effect of protein structure variation on drug response

Understanding how genetic variants translate into variability in phenotype is important in the field of personalized medicine. In this review, Lahti et al discuss combining knowledge of pharmacogenetics, the impact of genetic variation on protein structure, and the molecular mechanisms of how a drug works (pharmacodynamics), to provide a greater

Review of Translational Bioinformatics

Russ Altman has published a review of translational bioinformatics based on his annual reviews at the 2012 Summit on Translational Bioinformatics (TBI) held by AMIA (American Medical Informatics Association). Read the article online at Clinical Pharmacology & Therapeutics.

How might genetic variants of a single gene affect addiction to cigarettes and response to anti-cancer therapy?

The human CYP2A6 enzyme is involved in the metabolism of many different compounds - including those found in our diet and therapeutic drugs. We have recently written an updated Very Important Pharmacogene (VIP) Summary that is published in Pharmacogenetics and Genomics. CYP2A6 has a major role in the metabolism of nicotine,